Dermapharm Holding Valuation
| DMP Stock | 37.80 0.20 0.53% |
At this time, the firm appears to be overvalued. Dermapharm Holding shows a prevailing Real Value of USD30.23 per share. The current price of the firm is USD37.8. Our model computes the value of Dermapharm Holding from reviewing the firm fundamentals such as Profit Margin of 0.17 %, shares outstanding of 53.84 M, and Current Valuation of 2.68 B as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Dermapharm Holding's price fluctuation is very steady at this time. Calculation of the real value of Dermapharm Holding is based on 3 months time horizon. Increasing Dermapharm Holding's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Dermapharm Holding's intrinsic value may or may not be the same as its current market price of 37.80, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 37.8 | Real 30.23 | Hype 37.8 | Naive 38.36 |
The intrinsic value of Dermapharm Holding's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Dermapharm Holding's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Dermapharm Holding SE helps investors to forecast how Dermapharm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dermapharm Holding more accurately as focusing exclusively on Dermapharm Holding's fundamentals will not take into account other important factors: Dermapharm Holding Total Value Analysis
Dermapharm Holding SE is currently projected to have takeover price of 2.68 B with market capitalization of 2.1 B, debt of 574.72 M, and cash on hands of 161.38 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Dermapharm Holding fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.68 B | 2.1 B | 574.72 M | 161.38 M |
Dermapharm Holding Investor Information
About 65.0% of the company shares are held by company insiders. The book value of Dermapharm Holding was currently reported as 9.36. The company last dividend was issued on the 2nd of June 2022. Dermapharm Holding SE is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Dermapharm Holding Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Dermapharm Holding has an asset utilization ratio of 67.02 percent. This implies that the Company is making USD0.67 for each dollar of assets. An increasing asset utilization means that Dermapharm Holding SE is more efficient with each dollar of assets it utilizes for everyday operations.Dermapharm Holding Ownership Allocation
Dermapharm Holding holds a total of 53.84 Million outstanding shares. Dermapharm Holding SE shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.04 percent of Dermapharm Holding outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Dermapharm Holding Profitability Analysis
The company reported the revenue of 942.91 M. Net Income was 209.58 M with profit before overhead, payroll, taxes, and interest of 610.22 M.About Dermapharm Holding Valuation
The stock valuation mechanism determines Dermapharm Holding's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Dermapharm Holding based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Dermapharm Holding. We calculate exposure to Dermapharm Holding's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Dermapharm Holding's related companies.8 Steps to conduct Dermapharm Holding's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Dermapharm Holding's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Dermapharm Holding's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Dermapharm Holding's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Dermapharm Holding's revenue streams: Identify Dermapharm Holding's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Dermapharm Holding's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Dermapharm Holding's growth potential: Evaluate Dermapharm Holding's management, business model, and growth potential.
- Determine Dermapharm Holding's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Dermapharm Holding's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Dermapharm Stock Analysis
When running Dermapharm Holding's price analysis, check to measure Dermapharm Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermapharm Holding is operating at the current time. Most of Dermapharm Holding's value examination focuses on studying past and present price action to predict the probability of Dermapharm Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermapharm Holding's price. Additionally, you may evaluate how the addition of Dermapharm Holding to your portfolios can decrease your overall portfolio volatility.